Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.
Journal: Therapeutic advances in neurological disorders
Published: June 14, 2024
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.
Journal: Journal of central nervous system disease
Published: September 05, 2022
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 09, 2021
B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
Journal: Journal of neuroimmunology
Published: July 12, 2021
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Journal: Neurodegenerative disease management
Published: February 01, 2021
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial.
Journal: Annals of clinical and translational neurology
Published: November 17, 2020
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Journal: International journal of MS care
Published: August 31, 2020
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Journal: Therapeutic advances in neurological disorders
Published: July 23, 2020
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Journal: Multiple sclerosis and related disorders
Published: July 06, 2020
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Journal: Journal of neurology
Published: March 06, 2020
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 26, 2019
Last Updated: 09/26/2026